InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well… Read more
InnoCan Pharma Corporation (INNPF) - Total Assets
Latest total assets as of September 2025: $11.12 Million USD
Based on the latest financial reports, InnoCan Pharma Corporation (INNPF) holds total assets worth $11.12 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
InnoCan Pharma Corporation - Total Assets Trend (2015–2024)
This chart illustrates how InnoCan Pharma Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
InnoCan Pharma Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
InnoCan Pharma Corporation's total assets of $11.12 Million consist of 98.8% current assets and 1.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.1% |
| Accounts Receivable | $685.59K | 7.4% |
| Inventory | $3.32 Million | 35.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how InnoCan Pharma Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InnoCan Pharma Corporation's current assets represent 98.8% of total assets in 2024, an increase from 91.0% in 2015.
- Cash Position: Cash and equivalents constituted 54.1% of total assets in 2024, up from 17.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 35.8% of total assets.
InnoCan Pharma Corporation Competitors by Total Assets
Key competitors of InnoCan Pharma Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
China | CN¥3.66 Billion |
|
Taiyen Biotech Co Ltd
TW:1737
|
Taiwan | NT$8.26 Billion |
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
China | CN¥2.20 Billion |
|
Hunan Resun Co Ltd
SHE:001218
|
China | CN¥3.08 Billion |
|
Dencare (Chongqing) Oral Care Co. Ltd. A
SHE:001328
|
China | CN¥1.90 Billion |
|
Qingdao Kingking Applied Chemistry Co Ltd
SHE:002094
|
China | CN¥3.19 Billion |
|
C&S Paper Co Ltd
SHE:002511
|
China | CN¥9.17 Billion |
|
Anhui Deli Household Glass Co Ltd
SHE:002571
|
China | CN¥3.08 Billion |
InnoCan Pharma Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - InnoCan Pharma Corporation generates 3.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - InnoCan Pharma Corporation is currently not profitable relative to its asset base.
InnoCan Pharma Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.72 | 3.57 | 0.54 |
| Quick Ratio | 2.90 | 2.28 | 0.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.06 Million | $ 6.82 Million | $ -3.66 Million |
InnoCan Pharma Corporation - Advanced Valuation Insights
This section examines the relationship between InnoCan Pharma Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.89 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 33.4% |
| Total Assets | $9.26 Million |
| Market Capitalization | $501.28K USD |
Valuation Analysis
Below Book Valuation: The market values InnoCan Pharma Corporation's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: InnoCan Pharma Corporation's assets grew by 33.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for InnoCan Pharma Corporation (2015–2024)
The table below shows the annual total assets of InnoCan Pharma Corporation from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.26 Million | +33.43% |
| 2023-12-31 | $6.94 Million | -0.52% |
| 2022-12-31 | $6.98 Million | -44.52% |
| 2021-12-31 | $12.57 Million | +190.15% |
| 2020-12-31 | $4.33 Million | +67.85% |
| 2019-12-31 | $2.58 Million | +291.21% |
| 2018-12-31 | $660.00K | -54.16% |
| 2017-12-31 | $1.44 Million | -4.47% |
| 2016-12-31 | $1.51 Million | -15.19% |
| 2015-12-31 | $1.78 Million | -- |